Drug Trial Radar · NCT07232849
A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combined with other antitumor therapies in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.
Conditions
- Lung Cancer
Interventions
HRS-4508 tabletDrug
PartA :HRS-4508 tablet fixed dose+SHR-A1811 fixed dose PartB:HRS-4508 tablet fixed dose + Adebrelimab Injection fixed dose PartC:HRS-4508 tablet fixed dose +SHR-A1811 fixed dose + Adebrelimab Injection fixed dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity (DLT)Time frame: 2 month
- Maximum tolerated dose (MTD)Time frame: 2 month
- Determine dose recommendation (RP2D)Time frame: 6month
- The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)Time frame: 1 years
- Objective response rate (ORR)Time frame: 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Zhejiang Tumor Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.